Resmetirom

DRUG8 trials

Conditions

Cirrhosis, LiverHIV (Human Immunodeficiency Virus)HealthyMASHMASH - Metabolic Dysfunction-Associated SteatohepatitisMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseNASHNon-Alcoholic Fatty Liver Disease

Phase 1

A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

CompletedNCT07216313

Sagimet Biosciences Inc.Healthy

Start: 2025-09-30End: 2025-10-20Updated: 2026-01-23

Phase 2

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

RecruitingNCT07143968

Naga P. ChalasaniHIV (Human Immunodeficiency Virus), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease

Start: 2026-04-23End: 2027-11-01Target: 120Updated: 2026-07-30

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

RecruitingNCT07335601

Madrigal Pharmaceuticals, Inc.MASH - Metabolic Dysfunction-Associated Steatohepatitis

Start: 2025-12-29End: 2029-03-01Target: 120Updated: 2026-08-26

Study of Resmetirom in Children and Adolescents With MASH

RecruitingNCT07763015

Madrigal Pharmaceuticals, Inc.MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis

Start: 2026-08-01End: 2029-07-01Target: 61Updated: 2026-09-11

Phase 3

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

CompletedNCT04197479

Madrigal Pharmaceuticals, Inc.Non-Alcoholic Fatty Liver Disease

Start: 2019-12-16End: 2023-01-06Updated: 2023-09-05

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Active, not recruitingNCT04951219

Madrigal Pharmaceuticals, Inc.Non-Alcoholic Fatty Liver Disease

Start: 2021-07-09End: 2027-04-01Updated: 2026-05-27

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Active, not recruitingNCT05500222

Madrigal Pharmaceuticals, Inc.Cirrhosis, Liver, NASH

Start: 2022-08-26End: 2027-01-01Target: 845Updated: 2026-07-08

Phase 4

Resmiterom Efficacy & Safety in Patients With MASH

RecruitingNCT07249788

Nabiqasim Industries (Pvt) LtdMASH - Metabolic Dysfunction-Associated Steatohepatitis

Start: 2025-10-17End: 2026-12-31Target: 165Updated: 2025-12-03

2026-03-31

Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.

2026-02-26

The Cholate Challenge Test Quantified Baseline Functional Heterogeneity and Improvement in Response to Resmetirom in MASH-related Child-Pugh A Cirrhosis.

2025-08-29

NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials.

2025-01-019 citations

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.

2023-10-16275 citations

Design of the phase 3 <scp>MAESTRO</scp> clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis

Alimentary Pharmacology & Therapeutics2023-10-0271 citations

Biomarkers, Imaging, and Safety in a Well-compensated NASH Cirrhotic Cohort Treated With Resmetirom, a Thyroid Hormone Receptor-beta Selective Agonist, for 52 Weeks

Zeitschrift für Gastroenterologie2023-01-01

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Hepatology Communications2021-01-04176 citations